摘要
目的探讨酮咯酸氨丁三醇联合坦索罗辛治疗肾绞痛的临床效果和安全性。方法选取2019年7月~2020年6月收治的60例肾绞痛患者,按随机数字表法分为两组,各30例。对照组予以酮咯酸氨丁三醇联合屈他维林治疗,观察组采用酮咯酸氨丁三醇联合坦索罗辛治疗。比较两组临床疗效、起效时间和疼痛评分、复发率及不良反应情况。结果观察组治疗总有效率为93.33%,较对照组的73.33%高,差异有统计学意义(P<0.05);观察组起效时间为(16.52±2.17)min,短于对照组的(20.34±2.59)min,疼痛评分为(1.24±0.23)分,低于对照组的(1.89±0.25)分,差异均具有统计学意义(P<0.05);观察组复发率为6.67%,低于对照组的30.00%(P<0.05);两组不良反应相比,差异无统计学意义(P>0.05)。结论酮咯酸氨丁三醇联合坦索罗辛可提高肾绞痛治疗效果,缩短药物起效时间,加快疼痛感消失,且安全性高,复发率低。
Objective To investigate the clinical effect and safety of ketorolac tromethamine combined with tamsulosin in the treatment of renal colic.Methods A total of 60 patients with renal colic in our hospital from July 2019 to June 2020 were selected and divided into two groups according to the random number table method,with 30 cases in each group.The control group was treated with ketorolac tromethamine combined with drotaverine,and the observation group was treated with ketorolac tromethamine combined with tamsulosin.The clinical efficacy,onset time and pain score,recurrence rate and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.33%,which was higher than 73.33%in the control group,and there was a statistical difference(P<0.05);the onset time of the observation group was(16.52±2.17)min,which was shorter than that of the control group(20.34±2.59)min,the pain score was(1.24±0.23)points,which was lower than that of the control group(1.89±0.25)points,which was statistically different(P<0.05);the recurrence rate of the observation group was 6.67%,which was lower than that of the control group's 30.00%,there was a statistical difference(P<0.05);there was no statistical difference in adverse reactions between the two groups(P>0.05).Conclusion Ketorolac tromethamine combined with tamsulosin can improve the treatment effect of renal colic,shorten the time of drug onset,accelerate the disappearance of pain,and has high safety and low recurrence rate.
作者
骆建文
吴国新
叶镱
李栩聪
李庆坚
LUO Jian-wen;WU Guo-xin;YE Yi(Nanhai District People's Hospital of Foshan City,Foshan 528200,China)
出处
《中国处方药》
2021年第8期116-118,共3页
Journal of China Prescription Drug
基金
佛山市科技局医学类科技攻关项目(2018AB002212)。